KRAS Mutation Testing

BRAF Mutation Test is available free of charge for NHS funded patients when requested together with the KRAS mutation test*.

Mutations in the KRAS oncogene are frequently found in human cancers. They are common in colorectal cancer, pancreatic cancer and others. These mutations can help indicate prognosis and may be predictive of drug response.

Lab21 offers a highly sensitive, CE-Marked KRAS assay, which detects the 7 key mutations in the KRAS gene with 1% sensitivity.

Clinical data has established that 40% of colorectal tumours may carry a mutated KRAS gene and these tumours show little or no response to some therapies, including Panitumumab (Amgen) and Cetuximab (Erbitux, Merck). Prescreening for the presence of these mutations provides clinicians with an opportunity to target the drugs to a subset of patients more likely to respond well.

KRAS Mutation Test

To request the test, the first point of contact is Lab21 Customer Services, who handle:

  • Test Requests and Customer Support
  • Liaison with Sample Retention Sites for sample retrieval
  • Organisation of Sample logistics for testing
  • Reporting of the Results


Lab21 KRAS customer service

Tel:  UK: 0845 6777199
International:+44 (0)1223 395458
E Mail: KRAS@lab21.com
Fax: +44 (0)1223 395 451

Please note that special pricing for the BRAF mutation test may be available when BRAF mutation test is requested together with a KRAS mutation test. The BRAF and KRAS mutation tests can be performed from the same sample.

*This offer is valid until the end of 2010, and is available for NHS funded patients only. KRAS and BRAF Mutation Tests must be performed on the same sample.


  • Lièvre A, Blons H and Laurent-Puig P. (2010). Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 3-1-; 29(21): 3033-3043.
  • Fakih MM. (2010). KRAS mutation screening in colorectal cancer: From paper to practice. Clin Colorectal Cancer 2010; 9(1): 22-30.
  • E. Massarelli, M. Varella-Garcia, X. Tang, A. C. Xavier et al. (2007). KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res 2007; 13 (10).
  • William Pao, Theresa Y. Wang, Gregory J. Riely, Vincent A. Miller, Qiulu Pan, Marc Ladanyi et al. (2005). KRAS mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib.  PloS Medicine 2(1): 57-61.
  • D. A. Eberhard, B. E. Johnson, L.C. Amler, A. D. Goddard et al (2005). Mutations in the EGFR and in K-RAS are predictive and prognostic indicators in patients with NSCLC treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900-5909.
  • L. Toschi & F. Cappuzzo. (2007) Understanding the new genetics of responsiveness to EGFR tyrosine kinase inhibitors. Oncologist 12; 211-220.
  • Sae-Won Han, Tae-You Kim, Yoon Kyung Jeon, Pil Gyu Hwang et al. (2006). Optimization of Patient Selection for Gefitinib in Non-Small Cell Lung Cancer by combined analysis of Epidermal Growth Factor Receptor Mutation, K-RAS Mutation, and AKT Phosphorylation.  Clin Cancer Res 12(8):2538-2544.
  • Lievre A, Bachet J-B et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379.



Why choose this test?

Lab21 KRAS testing can provide an accurate determination of the mutation status of a patient.

  • Maximise patient selection of likely responders by identifying mutation positive patients, frequently missed by other less sensitive methods (eg sequencing)
  • Rapid turnaround
  • Clear clinical result pathways indicating likelihood of response
  • Sample types include DNA fresh, frozen or paraffin embedded tissue (PET)

5 daysFrom receipt of the patient sample at our laboratory, a report will be returned within 5 working days.